Navigation Links
Motilin in Medical News

Kosan Opens TIME-1 Pivotal Phase 3 Trial in Multiple Myeloma

... addition to its lead programs in Hsp90 inhibition and epothilones, Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is progressing in a Phase 1 trial as... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustai...

Kosan Announces November 8, 2007 Conference Call and Webcast of Third Quarter 2007 Financial Results

...ar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GER...
Motilin in Medical Technology

Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN ) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed ...

Kosan's Lead Hsp90 Inhibitor, Tanespimycin, Shows High Level of Activity in Trastuzumab Resistant/Refractory HER2-Positive Breast Cancer in a Phase 2 Trial

... epothilone products in order for Kosan to receive milestones or royalties, Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...

Kosan Announces Data Presentations at ASCO 2008 Annual Meeting

...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...

Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR

...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...

Kosan Initiates Phase 2 Trial of Epothilone KOS-1584 in Non-Small Cell Lung Cancer

...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...

Kosan Initiates Phase 2 Trial of Alvespimycin, Second-Generation Hsp90 Inhibitor, in HER2-Positive Metastatic Breast Cancer

...1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety tria... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's dependence upon the formation and sustai...

Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash

...r to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GERD). Thi...

Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting

... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 safety trial, with plans to pursue development in gastroesophageal reflux disease (GER...

Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial

... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...

Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma

... patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan ...
Motilin in Biological Technology

Development of Radioligand Binding Assays for the Motilin Receptor Using ScreenReady Targets.

Vronique Brechler, David Handfield, Martin Boissonneault, Esther Tremblay, Benoit Houle and Luc Mnard. Introduction Recent advances in combinatorial chemistry and genomics programs have led to an unprecedented increase in both the number of compounds and potential...

Kosan Appoints Pamela S. Cohen, M.D., as Chief Medical Officer

...Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...

Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference

... one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on...

Kosan Announces May 1, 2008 Conference Call and Webcast of First Quarter 2008 Financial Results

... one of the most successful classes of anti-tumor agents. KOS-1584 is in a Phase 2 clinical trial in patients with non-small cell lung cancer. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroesophagel reflux disease, is in a Phase 1 trial. For additional information on...

Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR

...S-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer for development in gastroeso... Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan'...

Kosan Restructures Workforce to Focus Resources on Lead Clinical Programs

...ty to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...

Kosan's Board of Directors Appoints Helen S. Kim as Chief Executive Officer

...ty to obtain valid and enforceable patents covering its product candidates; Kosan's dependence on its collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additional financing and Kosan's strategy to enter into partnering or licensing arrangements. These and ot...

Kosan Biosciences to Present at the Cowen and Company 28th Annual Health Care Conference

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan...

Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference

...lar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 is in Phase 1 clinical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is in a Phase 1 trial in gastroesophageal reflux disease (GERD). For additional information on Kosan...

Kosan Announces Senior Management Changes and Clinical Portfolio Priorities

...k and time to commercialization. -- Kosan's motilin agonist KOS-2187 has been licensed to Pfizer and i...ical trials in patients with solid tumors. Kosan's motilin agonist compound, KOS-2187, licensed to Pfizer, is...s collaboration with Pfizer for development of its motilin agonist product candidate; Kosan's need for additi...
Motilin in Biological Definition

Neurotransmitter

...Y) Opioids : corticotropin (ACTH) Beta-lipotropin dynorphin endorphin enkephaline leumorphin Secretins: secretin motilin glucagon vasoactive intestinal peptide (VIP) growth hormone-releasing factor (GRF) Somatostatins: somatostatin Tachykinins :...
Other Tags
(Date:5/5/2015)... Fla. (PRWEB) May 05, 2015 Baptist ... the Commission on Cancer (CoC) of the American College ... cancer program must meet more than 30 Commission on ... through a survey process, and maintain levels of excellence ... , When patients choose to seek care locally at ...
(Date:5/5/2015)... Atlanta, Georgia (PRWEB) May 05, 2015 ... Software of Victoria BC announced the Skedans Sensor ... The platform, for mobile and web app developers, provides ... from airborne and mobile sensors. , The Skedans Sensor ... at the intersection of the Internet of Things, Web ...
(Date:5/5/2015)... May 05, 2015 MAP Health Management, ... revenue cycle management for addiction treatment facilities, announced today ... President of Business Development. Mr. Mooney, who has more ... field, will be responsible for developing new strategic partnerships ... MAP’s core products and new initiatives. , Prior to ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Okyanos, the ... Lifestyle Report today. The study was conducted to determine ... as osteoarthritis and sports-related injuries have had ... stiffness was the most prevalent symptom reported at 73%, ... as walking, standing and bending over. Over half of ...
(Date:5/5/2015)... On April 8th, 2015, at the ... Recovery sponsored Durkin Entertainment’s “RockNRolla” EcoLuxe Lounge, a daylong ... sustainable product placement in TV and film. , ... of ecologically sound and socially conscious products and services, ... that makes appearances at various awards ceremonies and festivals ...
Breaking Medicine News(10 mins):Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 2Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 3Health News:Baptist Medical Center Jacksonville Receives National Cancer Reaccreditation 4Health News:Skedans Systems Announces Skedans Sensor Collaboration Platform at AUVSI's Unmanned Systems 2015 in Atlanta 2Health News:Jimmy Mooney, an Addiction Treatment Veteran, Named Vice President of Business Development at MAP Health Management, LLC 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 2Health News:Okyanos Study Finds Orthopedic Patients Plagued with Pain 3Health News:Choices Recovery Mishawaka Talks About Overcoming Adversity with Actor Matthew Ziff at the “RockNRolla Movie Awards” EcoLuxe Lounge 2
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/6/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... on the growing mobile commerce market, announced today ... MINIATURE, MULTI-PURPOSE ANTENNA METHOD AND SYSTEM FOR ... introduces a new revolutionary method and system to ... of miniature antenna modules for multiple purposes including ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
Other Contents